-
-
Login
A newly published correspondence in The Lancet Diabetes & Endocrinology has now reopened a debate that many healthcare systems believed had largely been settled: does wider CGM adoption always represent good value?
Wearable technology is becoming increasingly visible in professional tennis. From WHOOP recovery bands and continuous glucose monitors to Abbott's Lingo biosensor, here's who's wearing what at Wimbledon 2026 and why these devices are attracting attention both on and off the court.
From WHOOP straps and smart rings to the growing number of people wearing sensors on their upper arms, wearable health technology is becoming impossible to ignore. Lewis Hamilton, Harry Kane, Ollie Watkins and other elite athletes are helping drive a trend that is rapidly moving from professional sport into everyday life.
Teplizumab becomes the first NHS-approved treatment shown to delay the onset of type 1 diabetes. Given as a 14-day course of infusions before symptoms develop, the drug could postpone diagnosis by around two to three years and may signal the beginning of a new era in type 1 diabetes treatment.
Dexcom has agreed to acquire Nutrisense, bringing nutrition coaching and metabolic health services into its growing ecosystem. The deal offers the clearest sign yet that the future of CGM could extend far beyond traditional diabetes management.
EOFlow has secured a significant legal victory after a US appeals court overturned a $59.4 million judgment awarded to Insulet in the long-running dispute between the two patch pump manufacturers.
Insulet has recalled specific Omnipod pods after a fault linked to insulin under-delivery, high glucose and DKA.
Dexcom has warned that some G7 sensors intended for destruction after failing company quality standards were allegedly stolen and resold through unofficial supply channels, triggering concern across diabetes forums about counterfeit and diverted CGM devices entering circulation.
Beta Bionics says its Mint patch pump will launch in 2027, taking aim at market leader Omnipod with a tubeless insulin pump that promises FreeStyle Libre compatibility, smartphone control and a fully adaptive insulin algorithm. But the bigger opportunity may not be winning over existing Omnipod users at all.
Abbott has secured CE mark approval for Libre Duo, its new dual glucose-ketone sensor designed for people with diabetes. The launch could mark one of the biggest diabetes safety developments since hybrid-closed loop systems became mainstream.
Dexcom’s Investor Day gave the clearest public preview yet of G8 CGM. From launch timing and 15-day wear to a smaller sensor and future ketone sensing, here’s what users need to know.
Insulet has upgraded its 2026 revenue forecast after a strong start to the year, driven by global demand for Omnipod systems. Alongside growth, new details from regulators, analysts and safety updates provide a fuller picture of where the company — and the wider hybrid-closed loop market — is heading.
